Alembic Pharmaceuticals Ltd

Krishnan is a seasoned finance professional with over 22 years of experience across the pharmaceuticals, life sciences, telecom, and social sectors. He is a qualified Chartered Accountant (CA), Company Secretary (CS), and Cost and Management Accountant (CMA). Prior to joining Alembic, Krishnan served as Vice President and CFO at Syngene Scientific Solutions, a subsidiary of Syngene International, since May 2020. During his tenure, he played a crucial role in driving strategy, business finance, mergers & acquisitions, governance and risk management. He has also held key leadership positions at Vodafone and Tata Trusts. Krishnan brings with him expertise in business finance, M&A, scalable systems implementation, and governance frameworks, along with managing diverse finance teams. Meanwhile, the company also informed that R. K. Baheti, Director ' Finance and the current CFO, has relinquished his role as CFO effective 7 July 2025. However, he will continue to serve on the board as an executive director, in line with the terms of his appointment. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.37% to Rs 1,004.20 on the BSE. Powered by Capital Market - Live

Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). The first product 'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market. The second product 'MEC' is in development for the treatment of complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years. Alembic Pharma stated that the acquisition has been made to market the US FDA approved product and under-development product owned by the Utility in USA. The acquisition cost involves a cash component plus profit share out of future profits. The total amount payable is approximately $12 million. The payout would happen in staggered manner over period of time, depending on milestones achieved. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The scrip advanced 0.95% to currently trade at Rs 999.05 on the BSE. Powered by Capital Market - Live

Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved. Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI). -'Pivya' is an FDA approved product to treat uncomplicated UTIs in the US market. -'MEC' is a product in development for treatment of the complicated UTIs in the US market. As a product development company they have minimal turnover in last 3 years.Powered by Capital Market - Live

Jyoti CNC Automation Ltd, Raymond Ltd, TBO Tek Ltd, Raymond Lifestyle Ltd are among the other stocks to see a surge in volumes on NSE today, 30 June 2025.Alembic Pharmaceuticals Ltd recorded volume of 128.6 lakh shares by 14:14 IST on NSE, a 124.17 times surge over two-week average daily volume of 1.04 lakh shares. The stock gained 9.79% to Rs.1,063.80. Volumes stood at 1.17 lakh shares in the last session.Jyoti CNC Automation Ltd registered volume of 177.53 lakh shares by 14:14 IST on NSE, a 74.1 fold spurt over two-week average daily volume of 2.40 lakh shares. The stock slipped 5.83% to Rs.1,060.00. Volumes stood at 1.17 lakh shares in the last session.Raymond Ltd clocked volume of 91.06 lakh shares by 14:14 IST on NSE, a 21.3 times surge over two-week average daily volume of 4.28 lakh shares. The stock gained 14.44% to Rs.714.50. Volumes stood at 12.85 lakh shares in the last session.TBO Tek Ltd recorded volume of 10.93 lakh shares by 14:14 IST on NSE, a 12.52 times surge over two-week average daily volume of 87327 shares. The stock gained 0.56% to Rs.1,399.90. Volumes stood at 2.02 lakh shares in the last session.Raymond Lifestyle Ltd saw volume of 38.22 lakh shares by 14:14 IST on NSE, a 9.57 fold spurt over two-week average daily volume of 3.99 lakh shares. The stock increased 12.71% to Rs.1,377.60. Volumes stood at 12.04 lakh shares in the last session.Powered by Capital Market - Live

Jindal Worldwide Ltd, RattanIndia Power Ltd, AAVAS Financiers Ltd and Force Motors Ltd are among the other gainers in the BSE's 'A' group today, 30 June 2025.Alembic Pharmaceuticals Ltd surged 13.49% to Rs 1103 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 4.68 lakh shares were traded on the counter so far as against the average daily volumes of 5051 shares in the past one month. Jindal Worldwide Ltd soared 10.36% to Rs 61.58. The stock was the second biggest gainer in 'A' group. On the BSE, 4.29 lakh shares were traded on the counter so far as against the average daily volumes of 31183 shares in the past one month. RattanIndia Power Ltd spiked 6.94% to Rs 15.4. The stock was the third biggest gainer in 'A' group. On the BSE, 374.19 lakh shares were traded on the counter so far as against the average daily volumes of 193.98 lakh shares in the past one month. AAVAS Financiers Ltd spurt 6.20% to Rs 2115.45. The stock was the fourth biggest gainer in 'A' group. On the BSE, 33883 shares were traded on the counter so far as against the average daily volumes of 7113 shares in the past one month. Force Motors Ltd advanced 6.06% to Rs 15377.15. The stock was the fifth biggest gainer in 'A' group. On the BSE, 8028 shares were traded on the counter so far as against the average daily volumes of 12061 shares in the past one month. Powered by Capital Market - Live

The domestic equity benchmarks traded with modest losses in morning trade, weighed down by a mix of global and domestic factors. India's recent forex data revealed a decline in its reserves. Meanwhile, the Israel-Iran truce helped ease geopolitical tensions, and growing optimism over a potential US-India trade deal supported sentiment. Inflows from foreign institutional investors further contributed to the positive undertone. Even concerns around the July 9 U.S. tariff deadline took a backseat, as reports of a likely extension helped calm investor nerves. The Nifty traded below the 25,600 level. Private bank shares witnessed profit booking after advancing in the past two consecutive trading sessions. At 10:28 IST, the barometer index, the S&P BSE Sensex, declined 284.60 points or 0.33% to 83,778.85. The Nifty 50 index lost 82.05 points or 0.32% to 25,556.75. In the broader market, the S&P BSE Mid-Cap index rose 0.25% and the S&P BSE Small-Cap index jumped 0.62%. The market breadth was strong. On the BSE, 2,321 shares rose and 1,324 shares fell. A total of 222 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rallied 3.39% to 12.81. Economy: India's forex reserves dropped by USD 1.01 billion to USD 697.93 billion for the week ended June 20, the Reserve Bank of India said on Friday. For the week ended June 20, foreign currency assets, a major component of the reserves, dropped by USD 357 million to USD 589.06 billion, the data released on Friday showed. The gold reserves were down by USD 573 million to USD 85.74 billion during the week, the RBI said. The Special Drawing Rights (SDRs) declined by USD 85 million to USD 18.672 billion, the apex bank said. India's reserve position with the IMF also declined by USD 1 million to USD 4.45 billion in the reporting week, the apex bank data showed. Buzzing Index: The Nifty Private Bank index fell 0.31% to 28,417.85. The index rallied 1.34% in the past two consecutive trading sessions. Kotak Mahindra Bank (down 1.41%), HDFC Bank (down 0.60%), Axis Bank (down 0.52%) and ICICI Bank (down 0.50%) were the top losers. On the other hand, RBL Bank (up 3.73%), Bandhan Bank (up 2.35%) and Federal Bank (up 1.88%) edged higher. Stocks in Spotlight: Alembic Pharmaceuticals surged 8.40% after the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection. ITD Cementation India rallied 4.22% after the company secured an international marine contract worth $67.4 million (approximately Rs 580 crore) for jetty construction works related to the Ruwais LNG project in Abu Dhabi. Interarch Building Solutions rose 0.69%. The company announced that it has secured an order worth Rs 77 crore from Amara Raja Infra. Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Doxil Liposome Injection, of Baxter Healthcare Corporation. Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. According to IQVIA, the estimated market size for Doxorubicin Hydrochloride Liposome Injection single-dose vials is $29 million for the 12 months ending March 2025. Alembic now has a cumulative total of 224 ANDA approvals from the USFDA, including 201 final approvals and 23 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live

Alembic Pharmaceuticals announced that Viraj Save, Executive Vice President - Sales and Marketing has resigned from the said position and relieved w.e.f. 31 May 2025.Powered by Capital Market - Live

The inspection was conducted at the API-III facility from 17th March 2025 to 21st March 2025. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. Shares of Alembic Pharmaceuticals shed 0.78% to Rs 962.70 on the BSE.Powered by Capital Market - Live

Alembic Pharmaceuticals announced that the 15th Annual General Meeting(AGM) of the company will be held on 5 August 2025.Powered by Capital Market - Live